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Alzheimer’s disease (AD) is a terminal, age-related neurological syndrome exhibiting
progressive cognitive and memory decline, however AD patients in addition exhibit
ancillary neuropsychiatric symptoms (NPSs) and these include aggression. In this
communication we provide recent evidence for the mis-regulation of a small family of
genes expressed in the human hippocampus that appear to be significantly involved
in expression patterns common to both AD and aggression. DNA array- and mRNA
transcriptome-based gene expression analysis and candidate gene association and/or
genome-wide association studies (CGAS, GWAS) of aggressive attributes in humans
have revealed a surprisingly small subset of six brain genes that are also strongly
associated with altered gene expression patterns in AD. These genes encoded on
five different chromosomes (chr) include the androgen receptor (AR; chrXq12), brain-
derived neurotrophic factor (BDNF; chr11p14.1), catechol-O-methyl transferase (COMT;
chr22q11.21), neuronal specific nitric oxide synthase (NOS1; chr12q24.22), dopamine
beta-hydroxylase (DBH chr9q34.2) and tryptophan hydroxylase (TPH1, chr11p15.1 and
TPH2, chr12q21.1). Interestingly, (i) the expression of three of these six genes (COMT,
DBH, NOS1) are highly variable; (ii) three of these six genes (COMT, DBH, TPH1) are
involved in DA or serotonin metabolism, biosynthesis and/or neurotransmission; and
(iii) five of these six genes (AR, BDNF, COMT, DBH, NOS1) have been implicated in
the development, onset and/or propagation of schizophrenia. The magnitude of the
expression of genes implicated in aggressive behavior appears to be more pronounced
in the later stages of AD when compared to MCI. These recent genetic data further
indicate that the extent of cognitive impairment may have some bearing on the degree
of aggression which accompanies the AD phenotype.
Keywords: aggression-Alzheimer’s disease (AD), retrogenesis and schizophrenia, androgen receptor (AR), brain
derived neurotrophic factor (BDNF), tryptophan hydroxylase (TPH), neuronal specific nitric oxide synthase
(NOS1), catechol-O-methyl transferase (COMT), dopamine beta-hydroxylase (DBH)
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INTRODUCTION
There are currently 5.4 million Americans afflicted with
Alzheimer’s disease (AD) and one in nine Americans (11.1%)
over the age of 65 have AD1. In the later stages, about 45% of
all AD patients exhibit hostility and aggression towards their
fellow patients, caregivers and/or families (Borroni et al., 2010;
Ballard and Corbett, 2013; Fernàndez-Castillo and Cormand,
2016; Liu et al., 2016; Macfarlane and O’Connor, 2016; Wharton
et al., 2016). Aggressive behaviors in AD represent a significant
public healthcare concern and a social and clinical challenge for
institutionalized healthcare. The aggression associated with AD
is expressed as an overt and/or often harmful social interaction
with the primary intention of inflicting damage or other
unpleasantness upon other individuals that may occur either
without provocation or in retaliation. Aggressive behavior in AD:
(i) can take a variety of neuropsychiatric (NPS) forms; (ii) may be
communicated verbally or non-verbally; or (iii) may be expressed
physically. There are often multiple forms of aggression in the
AD patient including defensive (fear-induced) aggression,
predatory aggression, dominance aggression, inter-male
aggression, resident-intruder aggression, maternal aggression,
sex-related aggression, territorial aggression, isolation-induced
aggression and irritability-associated aggression (Fernàndez-
Castillo and Cormand, 2016; Liu et al., 2016; Macfarlane and
O’Connor, 2016; Wharton et al., 2016). Clinical and social
aspects of these types of AD-associated aggression are the
subject of several recent excellent reviews and include the most
up-to-date pharmacological strategies and therapeutic advances
to specifically address the aggressive AD phenotype (Ballard
and Corbett, 2013; Fernàndez-Castillo and Cormand, 2016; Liu
et al., 2016; Macfarlane and O’Connor, 2016; Wharton et al.,
2016). This original research article provides new data on the
overlap in the expression of brain-enriched genes in AD with
those implicated in aggression and incorporates the findings of
the most recent peer-reviewed research on emerging concepts of
the genetics linked to aggression in AD.
MATERIALS AND METHODS
Brain Sample Selection and Quality Control
Brain tissues were used in accordance with the institutional
review board (IRB)/ethical guidelines at the Louisiana State
University Health Sciences Center (LSUHSC) and the donor
institutions, and CERAD/NIH criteria were used to categorize
all AD tissues in accordance with established guidelines (Cui
et al., 2005, 2010; Lukiw et al., 2008; Montine et al., 2016). We
used mRNA expression profiles and DNA-array data from a
study of 12 mild-cognitively impaired (MCI) subjects (N = 12)
and their controls (N = 12), and 12 age-matched sporadic AD
hippocampal CA1 (N = 12) and their controls (N = 12). DNA
array data was performed using state-of-the-art microfluidics
hybridization platforms through an ongoing collaboration with
1http://www.alz.org/facts/?utm_source=google&utm_medium=search&utm_
campaign=google-grants&set.custom.wt=google-grants&gclid=CIjO58yy79
ICFUm2wAodlBIGmQ
Drs. Cristoff Eicken, Chris Hebel, Jason Mulcahey and Kyle
Navel at LC Sciences (Houston, TX, USA); mRNA expression
profiles and trends were independently corroborated and verified
using RT-PCR or Northern blotting in previously published
work from this lab (Cui et al., 2005, 2010; Lukiw et al., 2008;
Bhattacharjee et al., 2016). Both the MCI and AD groups had
their own control groups because of the age-differences between
MCI and AD and our understanding that age is the most
significant risk factor for the development of AD (Table 1).
All control, MCI and AD samples had the incidence of disease
verified by post-mortem evaluation; there were no significant
differences in age, gender, drug history, total RNA yield, RNA
quality, RNA integrity numbers (RIN) amongst the three groups
(see Table 1).
Expressed Genes Involved in AD and
Aggression
The data derived from our DNA/mRNA transcriptomic array
analysis were correlated and compared with those of a very
recent article by Fernàndez-Castillo and Cormand (2016) who
studied aggressive behavior in humans through the analysis of
genes and pathways identified via candidate gene association
and/or genome-wide association studies (CGAS, GWAS). Only
genes of the highest significance, either up-or-down-regulated,
were selected for further study, analysis and interpretation.
Just six genes were found to most significantly overlap in the
incidence of AD and aggression and these included the androgen
receptor (AR; chrXq12), brain-derived neurotrophic factor
(BDNF; chr11p14.1), catechol-O-methyl transferase (COMT;
chr22q11.21), neuronal specific nitric oxide synthase (NOS1;
chr12q24.22), dopamine beta-hydroxylase (DBH chr9q34.2)
and tryptophan hydroxylase (TPH1, chr11p15.1 and TPH2,
chr12q21.1; Figure 1).
RESULTS
Table 1 describes the case group (control for MCI (C1),
MCI, control for AD (C2) and AD), mean and 1 SD of
age, post-mortem interval (PMI), senile plaque (SP) and
neurofibrillary tangle (NFT) density and RNA quality control
parameters and RNA yield for the samples analyzed. There
were no significant differences in mean age, PMI, gender, RNA
quality control or RNA yield between MCI or AD and their
controls; MCI displayed 2.7–4 times the density of SP and NFT
as its control (C1); AD displayed 6.1–10 times the density of SP
and NFT as its control (C2); p < 0.05 (ANOVA); all samples
were of the highest purity available from multiple sources of
post-mortem brain human samples (Cui et al., 2005; Lukiw
et al., 2008; Zhao et al., 2016). High quality RNA samples
were subsequently analyzed using mRNA transcriptomic arrays
employing µParaflor Microfluidic Biochip Technologies that
interrogate the abundance and speciation of ∼27,000 human
mRNAs (LC Sciences, Houston, TX, USA); digitized data were
presented in the form of cluster diagrams (Cui et al., 2005;
Lukiw et al., 2008); Figure 1A describes the results in a
color-coded cluster diagram of the most changed genes in
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TABLE 1 | Summary of tissues used from each case group in this study.
Case group N Age∗1 x ± SD Age∗1 range PMI∗2 range SP/NFT∗3 RNA A260/280 RNA 28S/18S RNA yield∗4
C1 12 64.1 ± 8.1 64–78 2.5–3.5 1/3 2.07–2.15 1.45–1.55 1.15–1.35
MCI 12 64.8 ± 8.6 61–71 2.6–3.7 4/8 2.08–2.16 1.45–1.6 1.15–1.42
C2 12 71.5 ± 9.0 63–77 1.1–4.3 1/3 2.05–2.15 1.45–1.6 1.12–1.42
AD 12 72.1 ± 7.5 65–79 1.1–4.2 10/18 2.08–2.12 1.45–1.5 1.05–1.51
N = number of cases; age is age at time of death; x ± SD = mean plus or minus one standard deviation; age range refers to ranges of the individual age means;
post-mortem interval (PMI; death to brain freezing interval) range is the mean range in hours; SP/NFT, respectively senile plaque and neurofibrillary tangle counts, are
average lesion densities per square millimeter; RNA A260/280 and RNA 18S/28S ratios are indicative of high brain tissue RNA spectral quality; there was no significant
difference amongst control, MCI or AD total RNA yield; characterization of control, MCI and AD total RNA message; ∗1years; ∗2death to brain freezing interval in hours at
−81◦C; ∗3senile plaque (SP) and neurofibrillary tangle (NFT) counts are the mean lesion density per square millimeter (N = 12); ∗4average yield in total ug RNA/mg wet
weight brain tissue; hippocampal CA1 tissue samples were male or female Caucasian.
FIGURE 1 | Analysis of expressed genes common to both Alzheimer’s disease (AD) and aggression. (A) mRNA transcriptomic arrays were used to quantify
the levels of some of the most mis-regulated genes in mild-cognitive impairment (MCI) and AD brain samples compared to an MCI control (C1) and an independent
AD control (C2); these were compared to unchanging β-actin and/or α-tubulin (αTUB) levels in the same sample; gene expression patterns were next compared to
those also mis-regulated in “the aggressive phenotype” as recently reported by Fernàndez-Castillo and Cormand (2016); expressed gene alterations common to
both AD and aggression included the androgen receptor (AR), brain-derived neurotrophic factor (BDNF), catechol-O-methyl transferase (COMT), dopamine
beta-hydroxylase (DBH), nitric oxide synthase (NOS1) and tryptophan hydroxylase (TPH1 shown); genes including COMT and NOS1, and TPH1 to a lesser extent,
exhibit increased expression in the transition from MCI to AD; for example TPH1 showed a modest 0.2-fold increase in expression AD over MCI while NOS1 and
COMT displayed 2.8- and 2.9-fold increases in expression (p < 0.05, ANOVA); data for C1, C2, MCI and AD N = 12 cases each; the magnitude of expression for
each AD case is quantified in (B) for all 12 samples studied; great care was taken in the selection of control and age-matched AD samples; all brain samples were
from the hippocampal CA1; there were no significant differences in age, age range, gender, post-mortem interval (PMI) range, or RNA quality between the two
groups (Table 1); in (B) data for AR, BDNF, COMT, DBH, NOS1 and TPH1 are compared to controls for each sample (Table 1); interestingly, genes such as COMT,
BDNF and NOS1: (i) exhibit a trend for wider variation in their expression from sample to sample, and this is in agreement with reports of both up-and
down-regulation of their abundance in the literature (see above); and (ii) COMT and NOS1 display the largest general trend for up-regulation in AD vs. control (C2);
DBH exhibits a general trend for down-regulation (A). Genechip data for (B) is given in Supplementary data in Table S1. Other relevant DNA array data for these and
other genes expressed in AD and age-matched controls from our laboratories have been previously published (Colangelo et al., 2002; Cui et al., 2005; Lukiw et al.,
2008). Ongoing future studies will benefit from larger sample sizes, more homogeneous phenotypes and standardized measurements to identify expressed genes
that underlie aggressive behaviors which accompany the AD process.
MCI or AD vs. controls for an overlapping family of brain
genes involved in aggressive behaviors (Fernàndez-Castillo and
Cormand, 2016). These genes include AR, BDNF, COMT,
DBH, NOS1and TPH1 (TPH2 was not analyzed in these
assays). Individual AD signal yield expressed as fold-change
over controls are described in a scatter plot in Figure 1B.
Individual values >0 indicate up-regulation of expression and
values <0 indicate decreased expression. Interestingly, the
AR, BDNF and TPH1 gene expression patterns all displayed
a smaller general variability vs. a wider variability in the
expression of genes for COMT, DBH and NOS1 in the AD
brain (Figure 1B). This may explain, for example, reports
on both up- and down-regulated expression of COMT, DBH
and NOS1 in the AD brain (see below). The following is
a brief discussion of these six genes and their relevance to
aggression and AD, highlighting recent advances, particularly
within the last 10 months, in this understudied research
area.
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DISCUSSION
Androgen Receptor (AR, ANDR; chrXq12)
Circulating sex steroidal hormones such as testosterone that
play overlapping roles in cognition and aggression have been
widely implicated in the etiopathology of AD. While the
AR is abundantly expressed in both sexes, in AD expression
of the AR has been found to be generally down-regulated,
especially in aging males (Butchart et al., 2013; Dart et al.,
2013; Fedotova et al., 2016; Jia et al., 2016). Interestingly
the steroid-hormone testosterone-activated transcription factor-
signaling AR (ANDR) is known to exert regulatory effects
on synaptic plasticity and improve cognitive deficits in AD
patients and transgenic rodent models for AD (TgAD) but
the underlying mechanisms of androgenic action on cognitive
performance remain unclear. Testosterone, via the AR, increases
synaptophysin expression and improves synaptic plasticity and
cognitive metrics in both Aβ42 peptide-hippocampal injected
male rats and in the senescence-accelerated mouse prone
8 (SAMP8) TgAD murine model (Huo et al., 2016; Jia
et al., 2016). In a recent double-blind, placebo-controlled,
between-subject designed study, exogenous administration of
testosterone to healthy adult men potentiated the AR-enriched
hippocampus, amygdala and hypothalamus—anatomical regions
known to be involved in the stimulation of aggressive
behavior (Carré et al., 2016). Several studies have further
suggested that new treatments targeted toward preventing
synaptic pathology in AD or in TgAD models may involve
the use of androgen agonists and/or AR-acting drugs (Jia
et al., 2016; Pan et al., 2016). Interestingly, polyprenol
bioregulators such as Ropren (already used in AD treatment in
Russia and Australia) and polyprenol 2,3-dihydro derivatives
known as ‘‘dolichols’’ in gonadectomized rodents exhibit
decreased 5-hydroxyindoleacetic acid (5-HIAA)/5-HT ratios in
the hippocampus compared with DA and serotonin (5-HT)
levels, and are associated with increased anxiolytic (antianxiety)
behaviors in treated animals (Sugden et al., 2009; Fedotova et al.,
2016). Therefore it may be able to design useful drugs that are
able to negate aggression while promoting other useful aspects
of testosterone and AR signaling including improvement in
cognitive function.
Brain-Derived Neurotrophic Factor
(BDNF; chr11p14.1)
BDNF is the most widely distributed neurotrophin in the human
CNS and plays several pivotal roles in neural development,
survival, synaptic plasticity and cognition. This 247 amino
acid neurotrophin participates in axonal growth, pathfinding
and in the modulation of dendritic growth and morphology,
is a master regulator of synaptic plasticity and thus plays
a key role in memory formation and storage (Faria et al.,
2014; Nagata et al., 2014, 2016; Song et al., 2015). Therefore,
the involvement of BDNF in dementia has been extensively
investigated, and several reports indicate that BDNF expression
is decreased in hippocampus and neocortex of AD brains
(Figure 1; Peng et al., 2005; Song et al., 2015). Interestingly,
children with severe autism and aggression over-express the
AD-relevant beta-amyloid precursor protein (βAPP) at two or
more times the levels of children without autism and up to
four times more than children with mild autism; βAPP-derived
Aβ peptides can directly inhibit the proteolytic conversion of
BDNF from pro-BDNF thus reducing its levels (Sokol et al.,
2006; Tanila, 2017). Aβ peptides indirectly affect BDNF signaling
at synapses by interfering with its axonal transport in part
via interaction with the TrkB receptor (Durany et al., 2000;
Tanila, 2017). That BDNF expression is associated with multiple
independently-regulated promoters suggest that this unique
genomic structure may provide flexibility to regulate BDNF
signaling in distinct cell types and circuits that serve distinct
molecular functions some of whichmay be involved in aggressive
behaviors (Spalletta et al., 2010; Faria et al., 2014; Maynard
et al., 2016). It is interesting to speculate that episodic or
oscillatory forms of BDNF expression in AD may correlate
with aggressive outbreaks or contribute to them via complex
neurotrophic signaling pathways that are known to impact
behavioral phenotype.
Catechol-O-Methyl Transferase
(COMT; chr22q11.21)
COMT catalyzes the transfer of a methyl group from
S-adenosylmethionine to catecholamines, including the
neurotransmitters DA, epinephrine and norepinephrine,
resulting in one of the major degradative pathways of the
catecholamine transmitters. COMT appears to play a prominent
role in AD pathophysiology by affecting the metabolism of
catecholamine neurotransmitters such as DA in the prefrontal
cortex which are involved in working memory and executive
functioning (Serretti and Olgiati, 2012). Similarly, COMT
and DBH are directly involved with DA metabolism; this
neurotransmitter system appears to be specifically targeted by
the AD process (Martorana and Koch, 2014). While levels of
COMT in sporadic AD appear to be highly variable, either
up- or down-regulated, meta-analysis studies have identified
a possible association between AD and the COMT Val158Met
polymorphism in Asian but not in European populations
(Lee and Song, 2014; Sauerzopf et al., 2017). More recent
and comprehensive meta-analysis involving a review of 10
independent studies, which contained a total of 2777 AD
cases and 2829 controls indicated that the COMT Val158Met
polymorphism is associated with a decreased risk of AD in
the Asian population, but not in the Caucasian or overall
populations (Yan W. et al., 2016). Interestingly, genetic risk
score based on the accumulation of multiple risk alleles in
BDNF, COMT and APOE for AD combining multiple genetic
influences may be more useful in predicting late-life cognitive
impairment than individual polymorphisms (Wollam et al.,
2015). As for other neurotrophins and neurotransmitters
such as NOS1, periodic fluctuations in COMT expression in
AD may correlate with aggressive behaviors and contribute
to ‘‘behavioral dys-homeostasis’’ via complex and highly
interactive neurotrophic signaling pathways that contribute
to NPS events (Perroud et al., 2010; Clelland et al., 2016).
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Interestingly, prefrontal and temporal lobe dysfunction and
mutations in the COMT gene have been linked to agitation
and aggression in patients with schizophrenia, and deficits in
cognitive function predispose patients with AD to agitation
(Sachs, 2006; Clelland et al., 2016; Yan P. et al., 2016; Yan W.
et al., 2016).
Dopamine β-Hydroxylase
(DBH; chr9q34.2)
Dopamine beta-hydroxylase (DBH), an oxidoreductase
belonging to the copper-requiring type II, ascorbate-dependent
monooxygenase family and present in the synaptic vesicles
of postganglionic sympathetic neurons exists in both soluble
and membrane-bound forms, depending on the absence or
presence, respectively, of a signal peptide (Herrmann et al.,
2004; Godar and Bortolato, 2014; Ross et al., 2015; Godar
et al., 2016). DBH converts DA to norepinephrine (Ross et al.,
2015). Like COMT and NOS1, DBH exhibit wide inheritable
inter-individual variability in AD that is under genetic control
(Figure 1; Mustapic et al., 2013; Ross et al., 2015). Decreases in
DBH activity found in the early stages of AD may be a reflection
of loss of noradrenergic (NA) neurons, and the treatment of
early AD patients with selective NA reuptake inhibitors may
be indicated in early stages of AD to compensate for loss of
NA activities (Mustapic et al., 2013). The highly complex and
interactive nature of neurotrophins and neurotransmitters in
aggressive behaviors are underscored by recent observations
that serotonin and DA interactions in the prefrontal cortex,
along with other biological factors such as norepinephrine and
testosterone have been found to contribute to the aggressive
phenotype, as has monoamine oxidase A (MAOA) that catalyzes
the degradation of brain serotonin, norepinephrine and DA
(Haavik et al., 2008; Godar et al., 2016).
Neuronal Specific Nitric Oxide Synthase
(NOS1; chr12q24.22)
NOS1, a family of NO synthases which synthesize NO from
L-arginine is a pivotal mediator in neurotransmission, spatial
learning and cognition and has been repeatedly implicated in
the neurotoxicity associated with stroke and neurodegenerative
disease (Wultsch et al., 2007; Freudenberg et al., 2015; Austin
and Katusic, 2016; Miszczuk et al., 2016; Wang et al., 2016).
Interestingly, NO is a gaseous neurotransmitter that has also been
implicated in a wide range of pathological behaviors including
aggression, anxiety, depression and cognitive functioning.
NOS1 knockdown mice display a characteristic behavioral
profile consisting of reduced anxiety and aggression and
impaired cognitive metrics including learning and memory
(Wultsch et al., 2007; Miszczuk et al., 2016; Zhou et al.,
2016). Recent studies have shown that deficits of endothelial
NOS1 in AD play an important role in the phosphorylation of
the AD-related lesion tau in murine APP/PS1 TgAD models
(Austin and Katusic, 2016) while increased NOS-1 activity
and NO transmission in the hippocampus was evidenced
to modulate aggression (Miszczuk et al., 2016; Zhou et al.,
2016). Again, the seemingly multiphasic bioavailability of
NOS1 like that for COMT provides an equally oscillatory
potential for episodic and complex behaviors such as aggression
against a background of the inflammatory neurodegeneration
and disorganized thinking that in part characterize cognitive
disruption in AD.
Tryptophan Hydroxylase
(TPH1, chr11p15.1; TPH2, chr 12q21.1)
TPH catalyzes the first and rate limiting step in the
biosynthesis of the monoamine hormone, neurotransmitter
and neuromodulator serotonin (3-(2-aminoethyl)-1H-indol-
5-ol, 5-hydroxytryptamine; 5-HT). Remarkably, about 90% of
the human body’s total serotonin (and hence TPH biosynthetic
systems) are located in the neuroendocrine entero-chromaffin
cells in the human gastrointestinal (GI) tract, where it is used
to regulate intestinal movements and participate in GI-neural
tract signaling; the other 10% is synthesized by serotonergic
neurons of the CNS where it functions in the regulation
of neurite outgrowth, somatic morphology, growth cone
motility, synaptogenesis, and control of dendritic spine shape
and density, and behaviorally anger, aggression, mood, body
temperature, appetite, sleep, pain and cognition. Serotonin
acts via a heterogenic receptor family that includes G protein-
coupled receptors and ligand-gated ion channels (New et al.,
1998; Craig et al., 2004; Shearer et al., 2016; Wirth et al., 2016).
TPH is encoded by two separate enzymes: TPH1 produces
serotonin in the pineal gland and entero-chromaffin cells,
while TPH2 produces serotonin in the Raphe nuclei of the
brain stem and myenteric plexus. Interestingly, serotonin is
phylogenetically the oldest neurotransmission system present
involved in cognition and memory in both vertebrate and
invertebrate species, and pathological alterations in 5-HT
metabolism and/or down-regulation of serotonergic signaling
have been associated with various pathophysiological conditions
in the CNS including amyloidogenesis and SP formation,
hyper-phosphorylation of tau and NFT formation, two classical
aggregates that in part characterize AD brain neuropathology
(McClam et al., 2015; Panza et al., 2015; Butzlaff and Ponimaskin,
2016; Wirth et al., 2016). Due to the extensive serotonergic
denervation observed in AD and the important roles played by
serotonin in both behavior and cognition, this neurotransmitter
system has become a focus of dedicated research efforts to
identify novel pathways in Aβ peptide or NFT assembly and/or
aggregation (Butzlaff and Ponimaskin, 2016; Schneider et al.,
2016; Wirth et al., 2016). Serotonin has been found to increase
by 4-fold, respectively in AD raphe cell bodies over controls,
while in amygdala synaptic terminals 5-HT was decreased to
0.4-fold in the same AD cases; the accumulation of TPH and its
products in the raphe perikarya in AD as the result of diminished
transport of TPH to axon terminals and the accumulation
of oxidative metabolites of serotonin may contribute to the
degeneration of serotonergic neurons in AD (Burke et al., 1990;
Wirth et al., 2016). Recent studies have also shown that the
administration of selective serotonin reuptake inhibitors (SSRI)
to Tg-AD murine models both reduces the production of toxic
Aβ peptides and SP formation (Sheline et al., 2014; Butzlaff and
Ponimaskin, 2016). For example, SSRI such as the antianxiety/
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antidepressant citalopram hydrobromide (Celexa) has been used
in AD with varying success while antipsychotics remain the
pharmacological agents with most evidence to support their use
(Gallagher and Herrmann, 2015). On the other hand other recent
investigations, as part of the recent Citalopram for Agitation
in Alzheimer Disease (CitAD) study, indicate that higher doses
of SSRIs such as citalopram actually may trigger aggression
especially in patients with more severe cognitive impairment
encountered in the more advanced stages of AD (Schneider et al.,
2016).
Genetics of Aggression in Schizophrenia
With a median incidence of 152 cases/M (million) persons
(range 77–430 cases/M; c.i. 80%), schizophrenia is a relatively
common and perplexing neurological disorder characterized by
a series of NPSs that include abnormal psychosocial behavior,
anxiety, disorganized thinking and impaired cognition, reduced
social engagement and emotional expression, lack of motivation
and a significantly increased incidence of aggression (McGrath
et al., 2008; Soyka, 2011; Morris et al., 2015; Agarwal et al.,
2016; Cocchi et al., 2016; Janoutová et al., 2016; Nowak et al.,
2016). Globally, there are an estimated ∼25 million cases of
schizophrenia; males are more often affected than females (at
a ratio of 1.4 to 1), environmental and lifestyle risk factors
include birth in a winter month, at a high latitude, and in
an urban setting, and societal problems, such as long-term
unemployment, poverty, and homelessness are common
(Agarwal et al., 2016; Janoutová et al., 2016; Nowak et al.,
2016; van de Leemput et al., 2016). The average life expectancy
of people with schizophrenia is ∼10–25 years less than the
average, and in the US an estimated 16,000 people die from
behaviors related to, or caused by, schizophrenia each year
(Agarwal et al., 2016; Janoutová et al., 2016; Nowak et al.,
2016; van de Leemput et al., 2016). As with AD, aggressive
acts committed by patients with schizophrenia are a major
public health concern affecting patients, their families and
caregivers as well as organized healthcare and the criminal-
justice system. Also similar to AD, schizophrenia appears
to target high-level processing functions associated with the
neocortex and cortical synaptic connectivity; the genetic
contributions to schizophrenia are complex and multifactorial
with the integrated contributions of brain genes thought to
be centrally involved in auditory processing, altered mood
and behavior, anxiety and disorganized thought (Coyle et al.,
2016). As previously mentioned, five of these six genes (AR,
BDNF, COMT, DBH, NOS1) identified to be dysregulated
in this study in AD and aggression have been implicated in
the development, onset and/or propagation of schizophrenia.
Interestingly both ‘‘dopaminergic and serotoninergic hypotheses
for schizophrenia’’, involving an elevated genetically-based
capacity for striatal increased L-phenylalanine- and/or
L-tyrosine-derived DA biosynthesis, altered DA release and
defects in the tryptophan-derived serotonin (5-HT) and the
serotonin receptor, transporter and synaptic vesicle trafficking
systems have been implicated in several of the longest held
pathoetiologic- and pathogenic-hypotheses for schizophrenia
(Zhang et al., 2014; Baou et al., 2016; Cocchi et al., 2016;
Egbujo et al., 2016; Garay et al., 2016; Howes et al., 2017). The
overlapping participation of dopaminergic and serotoninergic
pathways, especially with DA-metabolizing COMT pathways
and serotonin (5-HT) reuptake inhibitors (SSRIs; Zoloft,
Paxil, Prozac and other antidepressants) and blockage of
serotonin transporter activities are remarkable. The duality
of DA and serotonin signaling is further underscored by the
actions, for example, of antipsychotic medications such as
Brexpiprazole (Rexultir; Lundbeck, Otsuka Pharmaceutical),
a partial agonist at DA D2 and serotonin 5-HT1A receptors
and an antagonist at serotonin 5-HT2A receptors, recently
approved by the US Food and Drug Administration (US-FDA)
for the treatment of acute or advanced cases of schizophrenia
(McEvoy and Citrome, 2016). Such dual-action antipsychotic
medications have shown positive outcomes, such as the
significant reduction of relapse in patients, in two independent
Phase 3 randomized controlled clinical trials for schizophrenia,
and Phase 3 trials are ongoing in patients with the aggressive
behaviors associated with AD (Marder et al., 2016; McEvoy and
Citrome, 2016).
Of related interest is the concept of ‘‘retrogenesis’’ as it
pertains to AD and schizophrenia. Retrogenesis predicts that:
(i) brain functions decline in the opposite order to which they
develop in humans or during evolution; and that (ii) these
anatomical regions of the brain that developed last may
be the first to deteriorate with the onset and propagation
of NPS illness. Put another way, the expression of genes
within anatomical regions known to direct high-level brain
processing functions, such as the integration of visual, auditory
and other sensory information associated with intellectual
abilities, behavior, memory and cognition are: (i) not only
especially vulnerable to the pathoetiology and pathobiology
of schizophrenia or the AD process; but (ii) are the same
brain regions that display a widespread loss of cortical synaptic
connectivity driven by multiple risk genes that adversely affect
synaptogenesis and synaptic integrity resulting in aggressive
behaviors, such as those periodically encountered in AD
(Ashford and Bayley, 2013; Douaud et al., 2014; Coyle et al.,
2016).
CONCLUSIONS AND SUMMARY
Just as lethargy, inactivity and passivity, and agitation and
hyperactivity lie at opposite ends of the NPS spectrum, apathy
and aggression lie at opposite ends of NPS behaviors associated
with AD. Certain NPSs are central features of both AD and
schizophrenia. Once thought to emerge primarily in the later
stages of these diseases, NPSs are currently understood to
manifest commonly in early disease stages and in prodromal
phases such as MCI. Aggression is a common NPS in
both MCI and AD, exhibits variability and fluctuation in its
presentation during the course of AD, is considerably more
prominent in the later stages of AD, is often associated
with psychosocial stressors, may be a response to perceived
or imagined threats, and requires dutiful intervention when
it causes the AD patient to be a threat to their family or
care-givers’ safety and well-being. Although aggressive behaviors
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in AD have received considerable research attention especially
over the last 20 years, the molecular-genetic mechanisms
involved in both functional and pathological aggression remain
incompletely understood and vast gaps in our knowledge
remain (Xing et al., 2012; Gallagher and Herrmann, 2015;
Smagin et al., 2015). On the other hand, progress is being
made on the appreciation that the regulation of complex
behaviors such as aggression is controlled by an increasingly
defined broad spectrum of highly interactive brain abundant
neurotrophins and/or neurotransmitters—these same signaling
molecules appear to have both triggering and preventing effects
on aggressive behaviors. Similarly, anti-aggression medications:
(i) have displayed hypervariable effects on aggressive behaviors
in humans and Tg-AD models depending on the medicinal
dose, age, gender and disease duration; and (ii) have displayed
both inhibitory and stimulating effects on aggressive behaviors,
depending largely upon the primary biological receptors where
they act and what brain anatomical regions are more exposed
to pharmacological treatment (Coyle et al., 2016; McEvoy
and Citrome, 2016). Ancillary factors that include diet and
other environmental factors, such as level of education, the
patient’s lifestyle, illicit drug use, ethnicity, the severity and
stage of cognitive impairment and inter-current neurological
disease have a considerable influence on the degree and extent
of NPSs. The interplay of microbial and host genetics and
other gene inducing factors are also becoming appreciated as
strong contributors to brain gene signaling that strongly impact
neurological health and the age-related development of CNS
disease (Zhao and Lukiw, 2015).
It is further interesting that the genetic signals associated
with AD and aggressive behavior involving the AR, BDNF,
COMT, DBH, NOS1 and TPH are all complex multifunctional
neurotrophic factors and/or neurotransmitters: (i) that are
evolutionarily ancient; and (ii) that can be highly interactive
in amplifying or reducing their role in aggressive behaviors
from both neuropsychological and interdisciplinary perspectives
(Narvaes and Martins de Almeida, 2014; McClam et al.,
2015; Coyle et al., 2016). Other factors that can impact the
regulation of gene expression including diurnal regulation,
oscillatory aspects, stochastic fluctuations of gene expression
and their variable transcriptional regulatory roles add further
layers of complexity to our understanding of the role of
genetics in the aggression associated with AD. It has recently
become apparent that biological mechanisms which drive
feedforward loops in NPS-relevant gene expression may have
strong influence on attenuating the stochasticity of brain gene
expression patterns (Barger, 2016; Shearer et al., 2016). The most
recent data on the genetics of aggression in AD demonstrate:
(i) that both the timescale of selective gene expression; and
(ii) fluctuations in the expression of those genes implicated
substantially affect the function and performance of biochemical
networks, and these factors further influence gene expression
plasticity, especially in the transcription-enriched environment
of human neurons (Figure 1; Barger, 2016; Shearer et al.,
2016). It is further interesting that this work is a prime
example of a remarkable congruency between GWAS-based
and DNA-array and transcriptomic-array-based findings which
both show similar fluctuations in the expression of gene
families important in both aggression and AD. With certainty:
(i) the application of novel comparative gene expression
approaches that include observations of temporal changes in
the activities of neurotrophic factors and/or neurotransmitters
merged with imaging technologies are certain to provide an
enduring foundation for the elucidation of what signaling genes
in the brain are crucial contributors to complex psychiatric
symptoms such as aggression; and (ii) the expression of
those NPS-related genes still represent a genuinely perplexing
aspect of altered behaviors associated with the AD process.
The path to scientific discovery invariably originates from
an awareness of what is unknown. What we do know
for certain is that the genetics of AD and aggression are
characterized by prominent intrinsic variabilities in the highly
interactive expression of genes that are complex, dynamic
and evolving, and this knowledge is sure to help guide and
shape the future direction of both neurotherapeutics and NPS
research.
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